User login
The new AGA Clinical Practice Update on Surveillance After Pathologically Curative Endoscopic Submucosal Dissection of Early Gastrointestinal Neoplasia in the United States: Commentary offers advice regarding surveillance intervals using endoscopy and other relevant modalities after endoscopic removal of dysplastic lesions and early GI cancers with endoscopic submucosal dissection (ESD) which were deemed pathologically curative.
Main takeaway: Patients with malignant lesions removed by curative ESD possess a higher risk of lymph node metastasis and should be surveilled more closely than those with resection dysplasia not associated with lymphatic spread.
The new AGA Clinical Practice Update on Surveillance After Pathologically Curative Endoscopic Submucosal Dissection of Early Gastrointestinal Neoplasia in the United States: Commentary offers advice regarding surveillance intervals using endoscopy and other relevant modalities after endoscopic removal of dysplastic lesions and early GI cancers with endoscopic submucosal dissection (ESD) which were deemed pathologically curative.
Main takeaway: Patients with malignant lesions removed by curative ESD possess a higher risk of lymph node metastasis and should be surveilled more closely than those with resection dysplasia not associated with lymphatic spread.
The new AGA Clinical Practice Update on Surveillance After Pathologically Curative Endoscopic Submucosal Dissection of Early Gastrointestinal Neoplasia in the United States: Commentary offers advice regarding surveillance intervals using endoscopy and other relevant modalities after endoscopic removal of dysplastic lesions and early GI cancers with endoscopic submucosal dissection (ESD) which were deemed pathologically curative.
Main takeaway: Patients with malignant lesions removed by curative ESD possess a higher risk of lymph node metastasis and should be surveilled more closely than those with resection dysplasia not associated with lymphatic spread.